Abstract:As epigenetic therapies continue to gain ground as potential treatment strategies for cancer and other diseases, compounds that target histone lysine methylation and the enzyme complexes represent a major frontier for therapeutic development. Clinically viable therapies targeting the activities of histone lysine methyltransferases (HKMT) and demethylases (HKDMs) have only recently begun to emerge following FDA approval of the EZH2 inhibitor tazemetostat in 2020 and remain limited to compounds targeting the well-studied SET domain–containing HKMTs and their opposing HKDMs. These include the H3K27 methyltransferases EZH2/EZH1, the singular H3K79 methyltransferase DOT1L, and the H3K4 methyltransferase MLL1/COMPASS as well as H3K9 and H3K36 methyltransferases. They additionally include the H3K4/9-preferential demethylase LSD1 and the H3K4-, H3K27-, and H3K36-preferential KDM5, KDM6, and KDM2 demethylase subfamilies, respectively. This Review discusses the results of recent clinical and preclinical studies relevant to all of these existing and potential therapies. It provides an update on advancements in therapeutic development, as well as more basic molecular understanding, within the past 5 years approximately. It also offers a perspective on histone lysine methylation that departs from the long-predominant "histone code" metaphor, emphasizing complex-disrupting inhibitors and proximity-based approaches rather than catalytic domain inhibitors in the outlook for future therapeutic development.

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)

Small Molecule KDM4s Inhibitors As Anti-Cancer Agents

Research progress in histone lysine demethylases inhibitors

Structural Simulation and Selective Inhibitor Discovery Study for Histone Demethylases KDM4E/6B from a Computational Perspective

Targeting N‐methyl‐lysine histone demethylase KDM4 in cancer: natural products inhibitors as a driving force for epigenetic drug discovery

Recent Advances with KDM4 Inhibitors and Potential Applications.

Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target

Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design

Epigenetic Targets and Drug Discovery Part 2: Histone Demethylation and DNA Methylation.

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Epigenetic targets and drug discovery: part 1: histone methylation.

Targeting histone demethylase KDM5B for cancer treatment

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Research Progress of Histone Demethylase JMJD and Its Inhibitors

Annual review of LSD1/KDM1A inhibitors in 2020

Therapeutic potential of targeting LSD1/ KDM1A in cancers

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmjC histone demethylases

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

Recent advances in inhibitors of lysine specific demethylase 1 in tumor therapies

Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges